Hepatocellular carcinoma (HCC)
Clinical trials for Hepatocellular carcinoma (HCC) explained in plain language.
Never miss a new study
Get alerted when new Hepatocellular carcinoma (HCC) trials appear
Sign up with your email to follow new studies for Hepatocellular carcinoma (HCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a smart drug starve liver tumors without harming healthy tissue?
Disease control Stopped earlyThis trial tests a new biologic called CSR02-Fab-TF, given directly into the liver's blood supply, for people with intermediate or limited advanced liver cancer that has not responded to prior treatment. The drug is designed to block blood vessels that feed the tumor while sparin…
Matched conditions: HEPATOCELLULAR CARCINOMA (HCC)
Early phase 1 • Sponsor: Koo Foundation Sun Yat-Sen Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Liver cancer drug trial halted early – what we know so far
Disease control Stopped earlyThis study tested a drug called cadonilimab in people with liver cancer who had surgery to remove their tumor but were at high risk of the cancer returning. The goal was to see if the drug could help keep the cancer away. The trial was stopped early, so the full results are not y…
Matched conditions: HEPATOCELLULAR CARCINOMA (HCC)
Phase 2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer drug INCB062079 tested in early trial
Disease control Stopped earlyThis early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.
Matched conditions: HEPATOCELLULAR CARCINOMA (HCC)
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC